Controlling the elution order of insulin and its analogs in sub‐/supercritical fluid chromatography using methanesulfonic acid and 18‐crown‐6 as mobile phase additives

Author:

Neumann Jonas12ORCID,Schmidtsdorff Sebastian12,Schmidt Alexander H.2ORCID,Parr Maria K.1ORCID

Affiliation:

1. Department of Biology, Chemistry, and Pharmacy, Institute of Pharmacy Freie Universität Berlin Berlin Germany

2. Chromicent GmbH Berlin Germany

Abstract

The purity analysis of therapeutic peptides can often be challenging, demanding the application of more than a single analytical technique. Supercritical fluid chromatography nowadays is a promising alternative to reversed‐phase liquid chromatography, providing orthogonal and complementary information. This study investigated its applicability for the separation of human insulin, its analogs and degradation products. A previously published method development protocol for peptides up to 2000 Da was successfully applied to the higher molecular weight insulins (6 kDa). A single gradient method was optimized for all insulins using a Torus DEA column (100 × 3.0 mm, 1.7 μm), carbon dioxide and a modifier consisting of methanol/acetonitrile/water/methanesulfonic acid (65:35:2:0.1, v/v/v/v). Consecutively, the crown ether 18‐crown‐6, which is well known to complex charged lysine sidechains and other amino functionalities, was added to the modifier to evaluate its impact on selectivity. A decreased retention and a shift in the elution order for the insulins were observed. An inverse effect on retention was found when combined with a neutral stationary phase chemistry (Viridis BEH).

Publisher

Wiley

Subject

Filtration and Separation,Analytical Chemistry

Reference41 articles.

1. The Current State of Peptide Drug Discovery: Back to the Future?

2. Cyclic peptide drugs approved in the last two decades (2001–2021)

3. EMA.Guideline on comparability of medicinal products containing biotechnology‐derived proteins as active substance—quality issues (revision 1). EMA/CHMP/BWP/247713/2012.2014.https://www.ema.europa.eu/en/documents/scientific‐guideline/guideline‐similar‐biological‐medicinal‐products‐containing‐biotechnology‐derived‐proteins‐active_en‐0.pdf

4. EMA.Guideline on non‐clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues. EMEA/CHMP/BMWP/32775/2005.2015.https://www.ema.europa.eu/en/documents/scientific‐guideline/guideline‐non‐clinical‐clinical‐development‐similar‐biological‐medicinal‐products‐containing_en‐0.pdf

5. International Conference on Harmonization.Harmonised tripartite guideline. Quality of biotechnological products: stability testing of biotechnological/biological products. Q5C.1995.https://database.ich.org/sites/default/files/Q5C%20Guideline.pdf

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3